1. Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: Glycol-split heparin-endostatin2 (GSHP-ES2).
- Author
-
Sun F, Wang Z, Yang Z, Li Y, Cui H, Liu C, Gao D, Wang F, and Tan H
- Subjects
- Angiogenesis Inhibitors chemical synthesis, Angiogenesis Inhibitors pharmacokinetics, Angiogenesis Inhibitors toxicity, Animals, Cell Line, Cell Movement drug effects, Chickens, Drug Stability, Endostatins chemical synthesis, Endostatins pharmacokinetics, Endostatins toxicity, Female, Glycopeptides chemical synthesis, Glycopeptides pharmacokinetics, Glycopeptides toxicity, Half-Life, Humans, Mice, Inbred BALB C, Oligopeptides chemical synthesis, Oligopeptides pharmacokinetics, Oligopeptides toxicity, Zebrafish, Angiogenesis Inhibitors pharmacology, Endostatins pharmacology, Glycopeptides pharmacology, Heparin chemistry, Oligopeptides pharmacology
- Abstract
Endostatin (ES) has attracted considerable attention for the treatment of anti-angiogenesis-related disorders. An 11-amino-acid peptide (ES2, IVRRADRAAVP) from the amino terminal of ES is of interest because it is the main active fragment of ES. However, both ES and ES2 have a poor stability and a short half-life, and other disadvantages need to be further resolved. Thus, we conjugated ES2 to glycol-split heparin derivatives (GSHPs) to yield the polymer-peptide conjugate, GSHP-ES2. This study showed that GSHP-ES2 exhibited increased stability, a wider pH activity range, better inhibition of endothelial cell proliferation, migration and tube formation in vitro, better anti-angiogenic activity and a longer half-life in vivo compared with ES2. These results also indicate that GSHP-ES2 has good potential for the treatment of angiogenesis-related diseases, either alone or in combination with other chemicals., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF